Edgar Filing: TITAN PHARMACEUTICALS INC - Form 4

TITAN PHA Form 4 January 04, 1	ARMACEUTICA	LS INC							
FORM		PPROVAL							
-	UNITED	STATES		SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549					3235-0287
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). StateMent of CHANGES IN BENEFICIAL OWNERSHIP SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 19 Section 17(a) of the Public Utility Holding Company Act of 1935 or S 30(h) of the Investment Company Act of 1940							nge Act of 1934, of 1935 or Secti	Estimated burden hou response	urs per
(Print or Type	Responses)								
1. Name and A Rubin Marc	2. Issuer Name and Ticker or Trading Symbol TITAN PHARMACEUTICALS IN [AMEX - TTP]				5. Relationship of Reporting Person(s) to Issuer IC (Check all applicable)				
(Last) 400 OYSTI BLVD., SU	3. Date of Earliest Transaction (Month/Day/Year) 01/02/2008			X Director 10% Owner X Officer (give title Other (specify below) below) President & Chief Ex Officer					
CO CANE	4. If Amendment, Date Original Filed(Month/Day/Year)			 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 					
SU. SAN F	RANCISCO, CA	94080					Person		
(City)	(State)	(Zip)	Tab	ole I - Non-l	Derivative	Securities A	cquired, Disposed	of, or Beneficia	lly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Date, if	3. Transactio Code (Instr. 8) Code V	Disposed (Instr. 3, 4	(A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Reminder: Rep	port on a separate line	e for each cla	ass of sec	urities bene	ficially ow	ned directly of	or indirectly.		
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.SEC 1474 (9-02)									
	Tab					posed of, or convertible :	Beneficially Owner securities)	d	

1. Title of	2.	3. Transaction Date	3A. Deemed	4. 5. Nui	nber of	6. Date Exercisable and	l I	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	TransactionDeriva	ative	Expiration Date		Underlying Securities

Edgar Filing: TITAN PHARMACEUTICALS INC - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securities (Month/Day/Year) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		/Year)	(Instr. 3 and 4)	
				Code V	(A) (I) Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Stock	\$ 1.64	01/02/2008		А	25,000	<u>(1)</u>	01/02/2018	Common Stock	25,000

Reporting Owners

Reporting Owner Name / A	ddress	Relationships						
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Director	10% Owner	Officer	Other				
Rubin Marc 400 OYSTER POINT BLV SUITE 505 SO. SAN FRANCISCO, C.	Х		President & Chief Ex Officer					
Signatures								
/s/ Marc Rubin	01/03/2008							
**C:	Dete							

<u>**</u>Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Options to purchase 50% of the shares vest on January 2, 2009 and the remaining options to purchase 50% of the shares vest in twelve equal monthly installments beginning on February 2, 2009.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.